871301-35-8

Basic information

• Product Name: (R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER
• Synonyms: (R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER;2H-Pyran-4-acetic acid, .alpha.-aminotetrahydro-, methyl ester, (.alpha.R)-;(R)-Methyl 2-aMino-2-(tetrahydro-2H-pyran-4-yl)acetate
• CAS NO: 871301-35-8
• Molecular Formula: C8H15NO3
• Molecular Weight: 173.21
• Mol File: 871301-35-8.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 244.1 °C at 760 mmHg
• Flash Point: 94.5 °C
• Appearance: /
• Density: 1.104 g/cm³
• Vapor Pressure: 0.0309mmHg at 25°C
• Refractive Index: 1.471
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER(871301-35-8)
• EPA Substance Registry System: (R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER(871301-35-8)

Safety Data

• Hazardous Substances Data: 871301-35-8(Hazardous Substances Data)

Usage

General Description

"(R)-AMINO-(TETRAHYDRO-PYRAN-4-YL)-ACETIC ACID METHYL ESTER" is a chemical compound that consists of an amino group, a tetrahydro-pyran-4-yl group, and an acetic acid methyl ester group. It is an organic compound with potential applications in the pharmaceutical industry, particularly in the development of new drugs and medications. The specific properties and potential uses of this compound will depend on its interactions with other chemicals and biological systems, as well as its effectiveness and safety in various applications. Further research and testing may be necessary to fully understand the potential benefits and risks of this compound.

InChI:InChI=1/C8H15NO3/c1-11-8(10)7(9)6-2-4-12-5-3-6/h6-7H,2-5,9H2,1H3

Upstream product

• 950192-18-4 racemic Cbz-pyranylglycine methyl ester 
• 477585-43-6 methyl 2-amino-2-(tetrahydro-2H-pyran-4-yl)acetate 
• 477584-90-0 methyl 2-(((benzyloxy)carbonyl)amino)-2-(dihydro-2H-pyran-4(3H)-ylidene)acetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 894789-28-7 (S)-N-Cbz-pyranyl glycine methyl ester 

Downstream Products

• 894789-28-7 (S)-N-Cbz-pyranyl glycine methyl ester 
• 1035279-38-9 C₃₃H₄₃N₅O₅ 
• 1035278-84-2 C₂₈H₃₅N₅O₃ 

Relevant articles and documents

Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation

The discovery of natural specialized pro-resolving mediators and their corresponding receptors, such as formyl peptide receptor 2 (FPR2), indicated that resolution of inflammation (RoI) is an active process which could be harnessed for innovative approaches to tame pathologies with underlying chronic inflammation. In this work, homology modelling, molecular docking and pharmacophore studies were deployed to assist the rationalization of the structure-activity relationships of known FPR2 agonists. The developed pharmacophore hypothesis was then used in parallel with the homology model for the design of novel ligand structures and in virtual screening. In the first round of optimization compound 8, with a cyclopentane core, was chosen as the most promising agonist (β-arrestin recruitment EC50 = 20 nM and calcium mobilization EC50 = 740 nM). In a human neutrophil static adhesion assay, compound 8 decreased the number of adherent neutrophils in a concentration dependent manner. Further investigation led to the more rigid cycloleucines (compound 22 and 24) with improved ADME profiles and maintaining FPR2 activity. Overall, we identified novel cyclopentane urea FPR2 agonists with promising ADMET profiles and the ability to suppress the inflammatory process by inhibiting the neutrophil adhesion cascade, which indicates their anti-inflammatory and pro-resolving properties.

AMIDE COMPOUND

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.